A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
University of Kansas Medical Center
University of Kansas Medical Center
AO GENERIUM
Centre Hospitalier Universitaire de Nīmes
University of Milano Bicocca
Technical University of Munich
Armaceutica, Inc.
Hospices Civils de Lyon
University of Basel
Blue Note Therapeutics
Willows Health
Assistance Publique - Hôpitaux de Paris
Glycostem Therapeutics BV
Sun Yat-sen University
University of Copenhagen
Trakya University
The Christie NHS Foundation Trust
Assistance Publique - Hôpitaux de Paris
Hutchmed
Acibadem University
M.D. Anderson Cancer Center
Shandong University
Assistance Publique Hopitaux De Marseille
Poitiers University Hospital
University of Erlangen-Nürnberg Medical School
University of British Columbia
University of British Columbia
Universidad Católica San Antonio de Murcia
Rhode Island Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Shandong Lanjin Pharmaceuticals Co.,Ltd
National Cancer Institute (NCI)
University Hospital, Clermont-Ferrand
Hadassah Medical Organization
NuRx Pharmaceuticals, Inc.
Community Cancer Care
East Valley Hematology and Oncology Medical Group